Amyotrophic Lateral Sclerosis (ALS)

Experimental oral therapy SPG302 may slow ALS progression

Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS

Spinogenix’s ALS hopeful to advance to registrational trial

First synaptic regenerative therapy for ALS gets orphan status

Regulatory actions for June 4, 2025

Spinogenix’s SPG302, the First Synaptic Regenerative Therapy to Treat ALS, Granted Orphan Drug Designation by the European Medicines Agency

Spinogenix’s ALS Breakthrough: A Los Angeles-Based Biotech’s Bold Leap Forward

FDA Authorizes Expanded Access Program for ALS Treatment SPG302

FDA Clears Phase 1/2 Clinical Trial for Spinogenix’s ALS Treatment SPG302

Spinogenix Announces FDA Clearance of IND Application Novel Therapy for the Treatment of ALS